In another key market of South Africa, during the current fiscal year Cipla is looking to strengthen its OTC (over-the-counter) business.
In the rest of world (RoW) market, the company will be focussing on continuing market leadership in key regions, it added.
For the current fiscal year, the company will focus on complex and differentiated assets and plans to file over 12 abbreviated new drug applications (ANDAs), while also ensuring compliance at all its facilities globally.
Cipla posted a net profit of Rs 1,492.44 crore for the 2018-19 fiscal as against Rs 1,416.57 crore in 2017-18.
Total revenue from operations for the last fiscal stood at Rs 16,362.41 crore. It was Rs 15,219.25 crore in the preceding financial year.